

1 **Title**

2 U-shaped-aggressiveness of SARS-CoV-2: Period between initial symptoms and clinical progression to COVID-19
3 suspicion. A population-based cohort study

4 **Short Title**

5 U-shaped aggressiveness of SARS-CoV-2

6 **Authors**

7 Dan Morgenstern-Kaplan^{1 ¶}, Bruno Buitano-Tang^{1 ¶}, Mercedes Martínez-Gil^{1 &}, Andrea Zaldívar-Pérez Pavón^{1 &},
8 Juan O. Talavera^{1,2*}.

9 **Affiliations**

- 10 1. Centro de Investigación en Ciencias de la Salud Anáhuac (CICSA), Facultad de Ciencias de la Salud,
11 Universidad Anáhuac México, Huixquilucan, Estado de México, México
12 2. Department of Medical Education and Research, ABC Medical Center, Mexico City, CDMX, Mexico.

13 *Corresponding Author

14 E-mail: jotalaverap@abchospital.com,

15 ¶ These authors contributed equally to this work.

16 & These authors also contributed equally to this work.

17

18

19

20

21

22 Abstract

23 **Background:** Early identification of different COVID-19 clinical presentations may depict distinct
24 pathophysiological mechanisms and guide management strategies.

25 **Objective:** To determine the aggressiveness of SARS-CoV-2 using symptom progression in COVID-19 patients.

26 **Design:** Historic cohort study of Mexican patients. Data from January-April 2020 were provided by the Health
27 Ministry.

28 **Setting:** Population-based. Patients registered in the Epidemiologic Surveillance System in Mexico.

29 **Participants:** Subjects who sought medical attention for clinical suspicion of COVID-19. All patients were
30 subjected to RT-PCR testing for SARS-CoV-2.

31 **Measurements:** We measured the Period between initial symptoms and clinical progression to COVID-19 suspicion
32 (PISYCS) and compared it to the primary outcomes (mortality and pneumonia).

33 **Results:** 65,500 patients were included. Reported fatalities and pneumonia were 2176 (3.32%), and 11568
34 (17.66%), respectively. According to the PISYCS, patients were distributed as follows: 14.89% in <24 hours,
35 43.25% between 1-3 days, 31.87% between 4-7 days and 9.97% >7 days. The distribution for mortality and
36 pneumonia was 5.2% and 22.5% in <24 hours, 2.5% and 14% between 1-3 days, 3.6% and 19.5% between 4-7 days,
37 4.1% and 20.6% >7 days, respectively ($p < 0.001$). Adjusted-risk of mortality was (OR [95% CI], p-value): <24
38 hours= 1.75 [1.55-1.98], $p < 0.001$; 1-3 days= 1 (reference value); 4-7 days= 1.53 [1.37-1.70], $p < 0.001$; >7 days=
39 1.67 [1.44-1.94], $p < 0.001$. For pneumonia: <24 hours= 1.49 [1.39-1.58], $p < 0.001$; 1-3 days= 1; 4-7 days= 1.48
40 [1.41-1.56], $p < 0.001$; >7 days= 1.57 [1.46-1.69], $p < 0.001$.

41 **Limitations:** Using a database fed by large numbers of people carries the risk of data inaccuracy. However, this
42 imprecision is expected to be random and data are consistent with previous studies.

43 **Conclusion:** The PISYCS shows a U-shaped SARS-CoV-2 aggressiveness pattern. Further studies are needed to
44 corroborate the time-related pathophysiology behind these findings.

45

46 **Key Words:** COVID-19, Epidemiology, Public Health, Pandemic, Mortality

47

48 **Introduction**

49
50 Coronaviruses are single-stranded RNA organisms capable of infecting humans and other animal species [1,2]. The
51 most recently discovered coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is cause
52 of the clinical entity denominated Coronavirus Disease 2019 (COVID-19). This virus initially spread in the Wuhan
53 province in China and later to the rest of the world, causing a pandemic [3]. Reported worldwide cases are
54 continuously growing and currently (as of July 3rd, 2020) there are over 10 million infected people confirmed and
55 over 500,000 fatalities. Global reports reveal case-fatality rate of 4.8% and more than half of the cases are in the
56 Americas region. In Mexico, over 230,000 cases have been reported, with over 28,000 fatalities and a case-fatality
57 rate of 12.3%, which by far surpasses the global estimate [4].

58 Every human in the world is susceptible to infection, for as the mean age of infected patients is 47 years, 87% of
59 patients lie between 30 and 79 years old. COVID-19 behaves more aggressively in older patients and in patients
60 undergoing chronic medical conditions such as obesity, diabetes [5,6], hypertension and other cardiovascular
61 diseases, increasing the risk of mortality in these populations [7,8]. Approximately 80% of cases are asymptomatic
62 with a mild disease course, while the other 20% can be accompanied of severe complications such as pneumonia,
63 Acute Respiratory Distress Syndrome (ARDS) and other secondary infections. Among these severe cases, 80%
64 correspond to people over 60 years. Many of these cases can be attributed to a severe clinical entity known as
65 “cytokine storm”, which causes a rise in serum levels of many pro-inflammatory mediators and provokes massive
66 tissue damage in several vital organs [7,9].

67 In patients who developed severe symptoms, dyspnea was reported between 8-12 days after onset of symptoms, and
68 some patients deteriorate into severe disease during the first week after onset of symptoms. This accelerated
69 worsening has been hypothesized to be caused by the cytokine storm and to thrombotic events that may be caused
70 by infection with SARS-CoV-2 [10].

71 Hospitalized patients have been thoroughly described and analyzed, with an average time between onset of
72 symptoms to intubation of 14.5 days, and a time from intubation to death ranging from 4-5 days [7,9,11]. A longer
73 period between onset of symptoms and first contact seeking medical attention has been associated with a poorer
74 outcome in these patients. However no in-depth studies have been conducted [12].

75 Until now, studies have been focused on patient-centered risk factors, while SARS-CoV-2 aggressiveness has been
76 established as provoking 20% of severe and critic patients [13],however, there are still many unanswered questions

77 concerning the clinical aggressiveness behavior of SARS-CoV-2. This study focuses on progression of symptoms as
78 a marker of such aggressiveness, using the Period between initial symptoms and clinical progression to COVID-19
79 suspicion (PISYCS) to determine the risk of severe disease and mortality.

80

81 **Methods**

82 **Study Design and Data Source**

83 A historic cohort study of Mexican patients that were classified as a suspect case of COVID-19 and sought medical
84 attention in either public or private health services in Mexico, was analyzed. Data was provided by the General
85 Directorate of Epidemiology of the Mexican Health Ministry, which is deidentified, publicly available online, and
86 registers all patients in the Epidemiologic Surveillance System of the 32 federal states in Mexico. This analysis was
87 done in all cases registered in this dataset up until April 25th, 2020, with a total of 65,500 patients [14]. The
88 Institutional Review Board of Anahuac University (Mexico City, Mexico) approved this study (Protocol approval
89 #202044).

90

91 **Variable Definition**

92 Our dataset includes demographic characteristics such as age, gender, location, health sector, underlying medical
93 conditions (obesity, diabetes, COPD, asthma, immunosuppression, hypertension, cardiovascular, chronic kidney
94 diseases, and other comorbid diseases), pregnancy status, tobacco use, and indigenous language speaker.
95 Furthermore, it references the dates of the onset of symptoms and the date of medical attention, including hospital
96 admission, as well as the presence of pneumonia. Regarding in-hospital decisions, data include results of RT-PCR
97 testing for SARS-CoV-2 (reported as positive, negative or pending), admission to the Intensive Care Unit (ICU) and
98 requirement of mechanical ventilation. Finally, the date of death of all deceased patients is reported.

99

100 **Data Analysis: Coding and substitution of variables**

101 The state where the patient sought attention was recoded according to the socio-economic level of that particular
102 state into low, middle and high level, based on the Gross Domestic Product (GDP) of that state, as reported by the

103 National Institute of Statistics and Geography (INEGI) [15]. The health sector variable was recoded in three
104 categories: private, with social security and without social security.

105 COVID-19 clinical suspicion was defined by the government health ministry's official guidelines, as presenting with
106 two of these symptoms: 1) cough, 2) fever or 3) headache, plus one or more of the following: 1) breathing difficulty,
107 2) sore or burning throat, 3) runny nose, 4) red eyes, 5) pain in muscles or joints, or 6) being part of these high-risk
108 groups: pregnancy, <5 or ≥60 years old, or having a chronic disease such as hypertension, diabetes mellitus, cancer
109 or HIV.

110 These indications were broadcast on television, radio, newspaper and internet platforms since the beginning of the
111 pandemic until July 1, 2020. Due to nationwide government issued stay-at-home orders, we assumed that medical
112 attention was sought only when these criteria were met.

113 Upon medical evaluation, patients were asked to report the date of onset of initial symptoms (any combination of
114 clinical features that appeared before meeting the previously mentioned criteria). Therefore, the Period between
115 initial symptoms and clinical progression to COVID-19 suspicion (PISYCS) was established as the number of days
116 between appearance of initial symptoms and the date in which the patients sought medical attention.

117 PISYCS

118 Initially, PISYCS was categorized in days (<1, 1, 2, 3, etc.), but to improve comprehension and data management,
119 adjacent days whose frequency of death remained in similar proportions, were grouped into 4 categories (<24 hours,
120 1-3 days, 4-7 days and >7 days). The primary outcomes were mortality and pneumonia. The presence of pneumonia
121 was used as an indicator of severe disease as reported in previous studies [7,9].

122 Missing data were substituted using the mode for the following categorical variables: Health Sector (338 patients,
123 0.5%), indigenous language speaker (1241, 2%), tobacco use (242, 0.4%), pregnancy status (166, 0.3%), diabetes
124 (255, 0.4%), COPD (245, 0.4%), asthma (251, 0.4%), immunosuppression (259, 0.4%), hypertension (241, 0.4%),
125 cardiovascular disease (252, 0.4%), obesity (220, 0.3%), chronic kidney disease (245, 0.4%), other comorbid
126 condition (331, 0.5%), admission to the ICU (12, <0.01%) and mechanical ventilation (12, <0.01%).

127

128 **Statistical Analysis**

129 Demographic features and comorbid conditions were initially compared between the four categories of PISYCS; age
130 was analyzed with a one-way ANOVA and the rest of the variables with Chi squared test analysis. Afterwards, we

131 performed a bivariate analysis comparing the four categories of PISYCS with the medical decisions made (result of
132 PCR testing for SARS-CoV-2, hospital admission, ICU, mechanical ventilation) and outcomes (mortality and
133 pneumonia) using the Chi squared test.
134 Finally, the four categories of PISYCS against primary outcomes -mortality and pneumonia-, were compared using a
135 multivariable logistic regression model. The model was adjusted in five steps for the following variables: age,
136 gender, indigenous language speaker, state's socioeconomic status, pregnancy, tobacco use, obesity, hypertension,
137 diabetes, asthma, COPD, cardiovascular disease, chronic kidney disease, immunosuppression, other comorbid
138 conditions. This model was repeated in four groups of patients within the sample, depending on their RT-PCR
139 testing result for SARS-CoV-2:

- 140 a. All patients: Every patient in the dataset regardless of their test result
- 141 b. Positives: Only patients with a positive test result
- 142 c. Negatives: Only patients with a negative test result
- 143 d. Pending: Only patients with pending results of the test

144 The PISYCS used as reference in the regression models, was 1-3 days based in the lower rate of mortality, observed
145 in the results of the bivariate analysis. Each logistic regression model is presented with the Odds Ratio (OR) and its
146 respective 95% Confidence Interval (CI_{95%}). Statistical significance was set at $p < 0.05$ and performed with SPSS
147 version 25.0 (IBM). The full model for the group of all patients can be found in the Supporting Information Section.
148

149 **Results**

150 The study population included 65,500 patients. Among them, the average age was 41 ± 17 years, 50.2%, were
151 women, 55.8% belonged to a high socioeconomic level, 27.7% to a medium and 16.5% to a low one, 4.6% of
152 patients were treated on a private health institution, 37.7% in a facility for patients with social security and 57.7%
153 attended to a public hospital for patients without social security. Of all the patients, 41% had at least one
154 comorbidity, hypertension being the most frequent in 17%, followed by obesity in 15.6% and diabetes 12.8%. In
155 addition, 9.9% reported tobacco use and 2.3% of women were pregnant. Mortality was observed in 2176 patients
156 (3.32%), and Pneumonia in 11568 patients (17.66%).

| | <i>Period between initial symptoms and clinical progression to COVID-19 suspicion (PISYCS)</i> | Global P Value |
|--|--|-----------------------|
|--|--|-----------------------|

157 According to PISYCS patients were distributed as follows: 14.89% in <24 hours, 43.25% between 1-3 days, 31.87%
158 between 4-7 days and 9.97% after 7 days, with no significant difference by gender. We compared PISYCS against
159 demographic features and comorbidities. A PISYCS of <24 hours was more frequent in older patients (25.7% in
160 patients > 80 years old vs. 15% in <30 years old) reversing in the period of 1-3 days (41.5% vs 48.4 %,
161 respectively), and returning to the initial behavior in subsequent periods. This same pattern was observed when
162 comparing PISYCS with the presence of all comorbidities, except for asthma and obesity. Demographic
163 Characteristics of all patients are summarized in Table 1.

164

165 **Table 1. Patient demographic characteristics according to Period between initial symptoms and**
166 **clinical progression to COVID-19 suspicion (PISYCS)**

| | | <24 Hrs (n=9759) | | 1-3 Days (n=28331) | | 4-7 Days (n=20877) | | >7 Days (n=6533) | | | |
|-------------------------------------|--------------------------|---------------------|---------|-----------------------|---------|-----------------------|-----------|---------------------|------------|------------------|------------------|
| | | N | % | N | % | N | % | N | % | | |
| Gender | Female | 4686 | 14.3%* | 14371 | 43.7% | 10562 | 32.1% | 3260 | 9.9% | <0.001 | |
| | Male | 5073 | 15.6% | 13960 | 42.8% | 10315 | 31.6% | 3273 | 10.0% | | |
| Age | < 30 | 2469 | 15.0%* | 7965 | 48.4% | 4732 | 28.7%** | 1302 | 7.9%*** | <0.001 | |
| | 30-49 | 3745 | 12.8% | 12813 | 43.6% | 9785 | 33.3% | 3016 | 10.3% | | |
| | 50-59 | 1430 | 14.7% | 3875 | 39.7% | 3321 | 34.1% | 1123 | 11.5% | | |
| | 60-69 | 1095 | 19.8% | 2006 | 36.2% | 1785 | 32.2% | 656 | 11.8% | | |
| | 70-79 | 615 | 21.9% | 1018 | 36.3% | 863 | 30.7% | 311 | 11.1% | | |
| | > 80 | 405 | 25.7% | 654 | 41.5% | 391 | 24.8% | 125 | 7.9% | | |
| | Mean (SD) | | 43(20)* | | 40 (18) | | 42 (17)** | | 44 (16)*** | | <0.001 |
| State's Socioeconomic Status | High | 5532 | 15.1%* | 15745 | 43.1% | 11352 | 31.1%** | 3921 | 10.7%*** | <0.001 | |
| | Medium | 2878 | 15.8% | 8027 | 44.2% | 5868 | 32.3% | 1402 | 7.7% | | |
| | Low | 1349 | 12.5% | 4559 | 42.3% | 3657 | 33.9% | 1210 | 11.2% | | |
| Health Sector | Private | 468 | 15.6%* | 1228 | 40.9% | 885 | 29.5%** | 418 | 13.9%*** | <0.001 | |
| | With SS | 4584 | 18.6% | 10515 | 42.6% | 7274 | 29.5% | 2321 | 9.4% | | |
| | Without SS | 4707 | 12.5% | 16588 | 43.9% | 12718 | 33.6% | 3794 | 10.0% | | |
| Indigenous Language Speaker | Yes | 98 | 14.4% | 277 | 40.8% | 242 | 35.6% | 62 | 9.1% | 0.20 | |
| | No | 9661 | 14.9% | 28054 | 43.4% | 20635 | 31.8% | 6471 | 10.0% | | |
| Pregnancy | Yes | 139 | 18.3% | 383 | 50.5% | 190 | 25.1%** | 46 | 6.1%*** | <0.001 | |
| | No | 9620 | 14.9% | 27948 | 43.2% | 20687 | 32.0% | 6487 | 10.0% | | |
| Tobacco Use | Yes | 946 | 14.5% | 2786 | 42.8% | 2122 | 32.6% | 661 | 10.1% | 0.49 | |
| | No | 8813 | 14.9% | 25545 | 43.3% | 18755 | 31.8% | 5872 | 10.0% | | |
| Diabetes | Yes | 1514 | 18.1%* | 3307 | 39.5% | 2684 | 32.1%** | 867 | 10.4%*** | <0.001 | |
| | No | 8245 | 14.4% | 25024 | 43.8% | 18193 | 31.8% | 5666 | 9.9% | | |
| COPD | Yes | 401 | 22.6%* | 685 | 38.6% | 535 | 30.2% | 153 | 8.6% | <0.001 | |
| | No | 9358 | 14.7% | 27646 | 43.4% | 20342 | 31.9% | 6380 | 10.0% | | |
| Asthma | Yes | 394 | 12.4%* | 1422 | 44.6% | 1034 | 32.5% | 336 | 10.5% | 0.001 | |
| | No | 9365 | 15.0% | 26909 | 43.2% | 19843 | 31.8% | 6197 | 9.9% | | |
| | Immunosuppression | Yes | 455 | 26.1%* | 697 | 40.0% | 429 | 24.6%** | 163 | 9.3% | <0.001 |
| | | No | 9304 | 14.6% | 27634 | 43.3% | 20448 | 32.1% | 6370 | 10.0% | |
| Hypertension | Yes | 1932 | 17.4%* | 4415 | 39.7% | 3593 | 32.3%** | 1194 | 10.7%*** | <0.001 | |
| | No | 7827 | 14.4% | 23916 | 44.0% | 17284 | 31.8% | 5339 | 9.8% | | |
| Cardiovascular Disease | Yes | 470 | 22.0%* | 820 | 38.3% | 627 | 29.3% | 224 | 10.5%*** | <0.001 | |
| | No | 9289 | 14.7% | 27511 | 43.4% | 20250 | 32.0% | 6309 | 10.0% | | |
| Obesity | Yes | 1381 | 13.5% | 4093 | 40.0% | 3633 | 35.5%** | 1119 | 10.9%*** | <0.001 | |
| | No | 8378 | 15.2% | 24238 | 43.9% | 17244 | 31.2% | 5414 | 9.8% | | |
| Chronic Kidney Disease | Yes | 435 | 28.1%* | 612 | 39.5% | 374 | 24.1%** | 129 | 8.3% | <0.001 | |
| | No | 9324 | 14.6% | 27719 | 43.3% | 20503 | 32.1% | 6404 | 10.0% | | |
| Other Comorbid Condition | Yes | 662 | 19.0%* | 1440 | 41.3% | 1059 | 30.4% | 323 | 9.3% | <0.001 | |
| | No | 9097 | 14.7% | 26891 | 43.4% | 19818 | 32.0% | 6210 | 10.0% | | |

167 SS= Social Security. COPD=Chronic Obstructive Pulmonary Disease. SD=Standard Deviation. Statistical
 168 Significance $p < 0.05$, * Significant Difference between periods of <24 hrs. and 1-3 days. ** Significant Difference
 169 between periods of 4-7 days and 1-3 days. *** Significant Difference between periods of >7 days and 1-3 days.

170
 171 Table 2 shows the initial medical decisions according to their PISYCS. More people were hospitalized in the first 24
 172 hours (43.2%), with a drop towards the period of 1-3 days (19.7%), and a slight increase in subsequent days. A
 173 similar phenomenon is observed in terms of admission to the ICU, with admission being 2.8% when the period is
 174 <24 hours, falling to 1.8% in 1-3 days, and gradually increasing to 2.7% in 4-7 days and 3.2% in >7 days. The
 175 proportion of patients under mechanical ventilation steadily increased over time, starting from 1.6% in the period of
 176 <24 hours, up to 2.9% in the period of >7 days.

177
 178 **Table 2. Medical Decisions according Period between initial symptoms and clinical progression to COVID-19**
 179 **suspicion (PISYCS).**

| | | Period between initial symptoms and clinical progression to COVID-19 suspicion (PISYCS) | | | | | | | | Global P Value | |
|------------------------------------|----------------------------|---|--------|--------------------|-------|--------------------|---------|------------------|----------|----------------|--------|
| | | <24 Hrs (n=9759) | | 1-3 Days (n=28331) | | 4-7 Days (n=20877) | | >7 Days (n=6533) | | | |
| | | N | % | N | % | N | % | N | % | | |
| Type of care | Ambulatory Care | 5547 | 56.8%* | 22742 | 80.3% | 15674 | 75.1%** | 4837 | 74.0%*** | <0.001 | |
| | Hospital Admission | 4212 | 43.2% | 5589 | 19.7% | 5203 | 24.9% | 1696 | 26.0% | | |
| Admission to the ICU | | 271 | 2.8%* | 503 | 1.8% | 563 | 2.7%** | 208 | 3.2%*** | | <0.001 |
| Mechanical Ventilation | | 155 | 1.6% | 479 | 1.7% | 525 | 2.5%** | 189 | 2.9%*** | | <0.001 |
| Result of RT-PCR Test ⁺ | Not Positive to SARS-CoV 2 | 7036 | 81.4%* | 19801 | 80.4% | 12672 | 69.8%** | 3910 | 66.5%*** | <0.001 | |
| | Positive to SARS-CoV-2 | 1601 | 18.6% | 4818 | 19.6% | 5462 | 30.2% | 1961 | 33.5% | | |

180 ICU= Intensive Care Unit. PCR= Polymerase Chain Reaction. SD= Standard Deviation

181 Statistical Significance $p < 0.05$, * Significant Difference between periods of <24 hrs and 1-3 days. ** Significant
 182 Difference between periods of 4-7 days and 1-3 days. *** Significant Difference between periods of >7 days and 1-3
 183 days. ⁺ Undefined were not included.

184
 185 Table 3 and Fig 1 show the risks for mortality and pneumonia related to PISYCS. A “U-shaped distribution” was
 186 observed according to PISYCS (<24 hrs., followed by 1-3 days, 4-7, and >7). The proportion of patients with
 187 Mortality was 5.2%, 2.5%, 3.6%, and 4.1% ($p < 0.001$), and for Pneumonia 22.5%, 14%, 19.5% and 20.6%

188 (p<0.001).The adjusted-risk of mortality for all patients evaluated for clinical suspicion of COVID-19 according to
 189 PISYCS, was for <24 hours OR of 1.75 (95% CI, 1.55 to 1.98, p = <0.001), 1-3 days OR = 1 (reference value), 4-7
 190 days, OR 1.53 (1.37-1.70, p = <0.001), and >7 days, OR 1.67 (1.44-1.94, p = <0.001), while for Pneumonia it was
 191 for <24 hours OR of 1.49 (95% CI, 1.39 to 1.58, p = <0.001), 1-3 days OR = 1 (reference value), 4-7 days, OR 1.48
 192 (1.41-1.56, p = <0.001), and >7 days, OR 1.57 (1.46-1.69, p = <0.001).

193

194 **Table 3. Mortality and Pneumonia among patients with COVID-19 according to the Period between initial**
 195 **symptoms and clinical progression to COVID-19 suspicion (PISYCS).**

| <i>Variable</i> | <i>Mortality</i> | | | <i>Pneumonia</i> | | |
|--------------------------------------|------------------|--------------------|----------------|------------------|--------------------|----------------|
| All Patients (N=65,500) | %* | OR (95% CI) | p-value | %* | OR (95% CI) | p-value |
| PISYCS (N) | | | | | | |
| < 24 Hours (9759) | 5.2% | 1.75 (1.55-1.98) | <0.001 | 22.5% | 1.49 (1.39-1.58) | <0.001 |
| 1-3 Days (28331) | 2.5% | 1 | 1 | 14% | 1 | 1 |
| 4-7 Days (20877) | 3.6% | 1.53 (1.37-1.70) | <0.001 | 19.5 | 1.48 (1.41-1.56) | <0.001 |
| > 7 Days (6533) | 4.1% | 1.67 (1.44-1.94) | <0.001 | 20.6% | 1.57 (1.46-1.69) | <0.001 |
| “p value” | <0.001 | | | <0.001 | | |
| SUBGROUP ANALYSIS | | | | | | |
| Positive Test (N=13,842) | | | | | | |
| PISYCS | | OR (95% CI) | p-value | | OR (95% CI) | p-value |
| < 24 Hours | | 2.11 (1.75-2.55) | <0.001 | | 1.66 (1.45-1.90) | <0.001 |
| 1-3 Days | | 1 | 1 | | 1 | 1 |
| 4-7 Days | | 1.42 (1.22-1.65) | <0.001 | | 1.69 (1.53-1.85) | <0.001 |
| > 7 Days | | 1.22 (1.00-1.49) | 0.053 | | 1.83 (1.62-2.07) | <0.001 |
| Negative Test (N=43,419) | | | | | | |
| PISYCS | | OR (95% CI) | p-value | | OR (95% CI) | p-value |
| < 24 Hours | | 1.55 (1.29-1.86) | <0.001 | | 1.58 (1.46-1.70) | <0.001 |
| 1-3 Days | | 1 | 1 | | 1 | 1 |
| 4-7 Days | | 1.00 (0.83-1.21) | 0.967 | | 1.10 (1.01-1.16) | 0.038 |
| > 7 Days | | 1.39 (1.10-1.81) | 0.014 | | 1.11 (1.00-1.24) | 0.061 |
| Test Result Pending (N=8,239) | | | | | | |
| PISYCS | | OR (95% CI) | p-value | | OR (95% CI) | p-value |
| < 24 Hours | | 1.41 (0.68-2.90) | 0.357 | | 0.80 (0.64-0.99) | 0.043 |
| 1-3 Days | | 1 | 1 | | 1 | 1 |
| 4-7 Days | | 1.22 (0.70-2.13) | 0.484 | | 2.03 (1.77-2.34) | <0.001 |
| > 7 Days | | 1.71 (0.78-3.74) | 0.182 | | 1.96 (1.57-2.44) | <0.001 |

196 *This Global Multiple Logistic Regression Model is adjusted for all demographic characteristics and comorbid*
 197 *conditions present in the patients. Adjustments for the group of all patients can be found in the Supporting*
 198 *Information Section.*

199 **Bivariate analysis between PISYCS vs. Mortality or Pneumonia.*

200

201 **Fig 1. U-Shaped Distribution of the odds ratio for the primary outcomes (mortality/pneumonia) vs. PISYCS.**

202 **Caption:** Association according to the Period between initial symptoms and clinical progression to COVID-19
203 suspicion (PISYCS) and the primary outcomes of the study (Mortality and Pneumonia), including all patients. A U-
204 shaped distribution is observed, with higher OR for PISYCS <24 hours and ≥ 4 days.

205

206

207 Discussion

208 In this study, we found an association concerning the Period between initial symptoms and clinical progression to
209 COVID-19 suspicion (PISYCS) with the risk of severe disease and mortality in patients with suspected COVID-19.
210 A “U shaped” distribution was observed, with a high risk of death and pneumonia when PISYCS is <24 hours (OR
211 1.75, and 1.49, respectively), with a decrease of this risk in 1-3 days (OR 1), and with an additional rise in
212 subsequent periods of 4-7 days (OR 1.53, and 1.48) and >7 days (OR 1.67 and 1.57).

213 The increased risk of mortality and pneumonia observed in patients with PISYCS <24 hours, may be associated with
214 the presence of a cytokine storm, which has been previously described as an early factor for severity[16]. This
215 phenomenon is due to the uncontrolled release of pro-inflammatory mediators that lead to apoptosis of epithelial and
216 endothelial lung cells, causing vascular extravasation, alveolar edema and hypoxia [17]This inflammatory response
217 in conjunction with the production of reactive oxygen species triggers an acute respiratory distress syndrome
218 (ARDS) leading to pulmonary fibrosis and death[18]. This could support the pharmacodynamic basis for the use of
219 corticosteroids as adjuvant therapy in patients with COVID-19, which has been reported in other studies [19].

220 Chronic use of inhaled corticosteroids may be the reason why asthmatic patients manifest less severe symptoms[20],
221 which was consistent with our results (See S1-S2 Tables).

222 The increased risk of mortality and pneumonia in patients with PISYCS ≥ 4 days, could be explained by the
223 thrombotic events that have been reported in patients with COVID-19. These events are caused by the excessive
224 inflammation produced by the virus and platelet activation with accompanying endothelial damage[21,22]. This
225 occurs once the virus has colonized the respiratory system, impairing microvascular permeability, helping it spread
226 even further. Hemostatic disorders are established by the presence of thrombocytopenia, and an increase in the D-
227 dimer and fibrinogen, for which the use of antithrombotic therapies has been suggested[21,23].

228 Additionally, an increased risk of lung superinfections must be considered. So far, bacterial and fungal pneumonias
229 have been the most common etiologies. A study conducted in Wuhan, China reported a rate of lung superinfection
230 from 5-27% in adults with COVID-19 [24]. Historically, superinfections have been associated with increased
231 mortality in other viral respiratory infections, such as influenza [25].

232 Our findings may have further clinical implications if the pathophysiological processes were to be confirmed. The
233 PISYCS could be useful as a prognostic marker and a decision-making tool for clinicians. Identifying individuals at
234 higher risk of developing early-onset complications (with a PISYCS <24 hours) could justify a more aggressive
235 treatment plan and monitorization strategies, focused on preventing complications of cytokine storm and ARDS.
236 Additionally, patients with a higher risk of late-onset complications (with a PISYCS \geq 4 days) could be identified
237 and treated accordingly, justifying the use of thromboprophylaxis, preventing superinfections.

238 The PISYCS could also prove useful as a research categorization parameter for clinical studies exploring timing and
239 efficacy of therapeutics. Immunomodulatory agents (such as IL-6 antagonists) and corticosteroids may only prove
240 beneficial for patients with a PISYCS of < 24 hours and may further increase the risk of late-onset complications
241 (superinfections) if used in a later PISYCS category [24].

242

243 Using a database fed by large numbers of people carries its risk, such as data inaccuracy. However, this imprecision
244 is expected to be random and data are consistent with results of previous studies. Furthermore, we set April 25th,
245 2020 as our cut-off date with the aim of including patients treated at an early stage of the pandemic in Mexico, at a
246 time when hospitals were not yet working at overcapacity. This increases the probability of good quality of
247 healthcare, decreases confounding factors for the outcomes evaluated because all required medical decisions could
248 be made and were not limited by medical resources available at the time (i.e. number of ventilators or ICU beds).
249 Plenty of studies have described the incubation period and hospital stay of affected patients[7,26,27]. However,
250 nobody has considered the progression of symptoms in patients with COVID-19 (PISYCS), as a guide for
251 explaining the time-specific pathophysiology associated with the U-Shaped SARS-CoV-2 aggressiveness. Further
252 studies are needed to corroborate the time-related pathophysiology behind these findings. Eventually, this could help
253 identify specific therapies aimed towards the temporal progression of the disease.

254

255

256 **Acknowledgments**

257 The authors report no conflicts of interest regarding the present study. The Dataset used for all statistical analyses is
258 available in the Mendeley Data Repository Online at: <http://dx.doi.org/10.17632/k6cw45366d.1>

259

260

261 **References**

- 262 1. Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. *Lancet*. 1966;1:
263 76–77. doi:10.1016/s0140-6736(66)92364-6
- 264 2. Velavan TP, Meyer CG. The COVID-19 epidemic. *Trop Med Int Heal*. 2020;25: 278–280.
265 doi:10.1111/tmi.13383
- 266 3. Battagay M, Kuehl R, Tschudin-Sutter S, Hirsch HH, Widmer AF, Neher RA. 2019-novel Coronavirus
267 (2019-nCoV): estimating the case fatality rate - a word of caution. *Swiss Med Wkly*. 2020;150: w20203.
268 doi:10.4414/smw.2020.20203
- 269 4. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. In: WHO [Internet]. 2020.
270 Available: <https://covid19.who.int/>
- 271 5. Maddaloni E, D’Onofrio L, Alessandri F, Mignogna C, Leto G, Coraggio L, et al. Clinical features of
272 patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I). *Diabetes Res*
273 *Clin Pract*. 2020;169: 1–7. doi:10.1016/j.diabres.2020.108454
- 274 6. Maddaloni E, D’Onofrio L, Alessandri F, Mignogna C, Leto G, Pascarella G, et al. Cardiometabolic
275 multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors:
276 A multicentre retrospective study (CoViDiab II). *Cardiovasc Diabetol*. 2020;19: 1–11. doi:10.1186/s12933-
277 020-01140-2
- 278 7. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients:
279 Characteristics and prognostic factors based on 4-week follow-up. *J Infect*. 2020.
280 doi:10.1016/j.jinf.2020.03.019
- 281 8. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment
282 Coronavirus (COVID-19) - StatPearls - NCBI Bookshelf. *StatPearls*. 2020. pp. 1–17. Available:
283 <https://www.ncbi.nlm.nih.gov/pubmed/32150360>
- 284 9. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a
285 new coronavirus of probable bat origin. *Nature*. 2020;579: 270–273. doi:10.1038/s41586-020-2012-7
- 286 10. Centers For Disease Control. Interim Clinical Guidance for Management of Patients with Confirmed
287 Coronavirus Disease (COVID-19). 2020. Available: <https://www.cdc.gov/coronavirus/2019->

- 288 [ncov/hcp/clinical-guidance-management-patients.html](https://www.cdc.gov/covid/hcp/clinical-guidance-management-patients.html)
- 289 11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult
290 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395: 1054–1062.
291 doi:10.1016/S0140-6736(20)30566-3
- 292 12. Liang W, Guan W, Li C, Li Y, Liang H, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised
293 patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide
294 analysis of China. *Eur Respir J*. 2020;55: 2000562. doi:10.1183/13993003.00562-2020
- 295 13. Azoulay E, Fartoukh M, Darmon M, Géri G, Voiriot G, Dupont T, et al. Increased mortality in patients with
296 severe SARS-CoV-2 infection admitted within seven days of disease onset. *Intensive Care Med*. 2020;46:
297 1714–1722. doi:10.1007/s00134-020-06202-3
- 298 14. Direccion General de Epidemiologia, Secretaría de Salud. Datos Abiertos - Bases Históricas. 2020.
299 Available: [https://www.gob.mx/salud/documentos/datos-abiertos-bases-historicas-direccion-general-de-](https://www.gob.mx/salud/documentos/datos-abiertos-bases-historicas-direccion-general-de-epidemiologia)
300 [epidemiologia](https://www.gob.mx/salud/documentos/datos-abiertos-bases-historicas-direccion-general-de-epidemiologia)
- 301 15. INEGI. Comunicado De Prensa Núm . 384 / 19 31 De Julio De 2019 El Inegi Da a Conocer Los Resultados
302 De La Encuesta Nacional De Ingresos Y Gastos De Los Hogares (Enigh) 2018. Comun prensa INEGI.
303 2019.
- 304 16. Henderson LA, Canna SW, Schulert GS, Volpi S, Lee PY, Kernan KF, et al. On the alert for cytokine storm:
305 Immunopathology in COVID-19. *Arthritis Rheumatol*. 2020;72: 1059–1063. doi:10.1002/art.41285
- 306 17. Pascarella G, Strumia A, Piliago C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and
307 management: a comprehensive review. *J Intern Med*. 2020;288: 192–206. doi:10.1111/joim.13091
- 308 18. Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of
309 COVID-19 pneumonia. *Cytokine Growth Factor Rev*. 2020;53: 38–42. doi:10.1016/j.cytogfr.2020.04.002
- 310 19. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in
311 Hospitalized Patients with COVID-19: Preliminary Report. *medRxiv*. 2020; 2020.06.22.20137273.
312 doi:10.1101/2020.06.22.20137273
- 313 20. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic. *Clin Rev Allergy Immunol*.
314 2020. doi:10.1007/s12016-020-08797-3
- 315 21. Bikdeli B, Madhavan M V., Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and Thrombotic

- 316 or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC
317 State-of-the-Art Review. *J Am Coll Cardiol.* 2020;75: 2950–2973. doi:10.1016/j.jacc.2020.04.031
- 318 22. Cannegieter SC, Klok FA. COVID-19 associated coagulopathy and thromboembolic disease: Commentary
319 on an interim expert guidance. *Res Pract Thromb Haemost.* 2020;4: 439–445. doi:10.1002/rth2.12350
- 320 23. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. *Clin Immunol.* 2020;215.
321 doi:10.1016/j.clim.2020.108427
- 322 24. Clancy CJ, Nguyen MH. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development:
323 What Can We Expect? *Clin Infect Dis.* 2020. doi:10.1093/cid/ciaa524
- 324 25. Rynda-Apple A, Robinson KM, Alcorn JF. Influenza and bacterial superinfection: Illuminating the
325 immunologic mechanisms of disease. *Infect Immun.* 2015;83: 3764–3770. doi:10.1128/IAI.00298-15
- 326 26. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus
327 disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. *Ann Intern*
328 *Med.* 2020;172: 577–582. doi:10.7326/M20-0504
- 329 27. Sun Q, Qiu H, Huang M, Yang Y. Lower mortality of COVID-19 by early recognition and intervention:
330 experience from Jiangsu Province. *Ann Intensive Care.* 2020;10: 2–5. doi:10.1186/s13613-020-00650-2

331

332

333

334

335

336

337

338

339

340

341 **Supporting Information**

342 **S1 Table. Stepwise analyses for binary logistic regression with Mortality as outcome for all patients in the**
343 **study.**

344 **S2 Table. Stepwise analyses for binary logistic regression with Pneumonia as outcome for all patients in the**
345 **study.**

Figure 1. All Patients:
PISYCS vs. Primary Outcomes (OR, 95% CI)

